Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients

13Citations
Citations of this article
62Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Many paediatric patients with cancer experience significant chemotherapy side effects. Predisposition to drug reactions is governed by single nucleotide polymorphisms (SNPs). We performed a systematic review of the literature from 2006 through 2016. Outcomes of interest included patient characteristics, cancer type drug of interest, genes investigated, toxicity identified and genetic polymorphisms implicated. The primary toxicities studied were neurotoxicity cardiotoxicity, osteonecrosis, and thromboembolism and hypersensitivity reactions. The retrieved studies were grouped according to toxicity reported and SNP associations. This review highlights the discoveries to date in pharmacogenomics and paediatric oncology along with highlighting some of the important limitations in the area.

Cite

CITATION STYLE

APA

Conyers, R., Devaraja, S., & Elliott, D. (2018, April 1). Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients. Pediatric Blood and Cancer. John Wiley and Sons Inc. https://doi.org/10.1002/pbc.26937

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free